0001175151 false 0001175151 2021-10-07 2021-10-07 iso4217:USD xbrli:shares iso4217:USD xbrli:shares





Washington D.C. 20549





Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934


Date of Report (Date of Earliest Event Reported): October 7, 2021



(Exact name of registrant as specified in its charter) 


Delaware   001-36792   98-0373793
(State or other jurisdiction of incorporation)   (Commission File Number)   (I.R.S. Employer Identification No.)


7 Deer Park Drive, Suite K,

Monmouth Junction, New Jersey

(Address of principal executive offices) (Zip Code)


Registrant’s telephone number, including area code: (732) 329-8885


Not Applicable

(Former name or former address, if changed since last report.)


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):


  ¨  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)


  ¨  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)


  ¨  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))


  ¨  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))


Securities registered pursuant to Section 12(b) of the Act:


Title of each class Trading Symbol(s) Name of each exchange on which registered
common stock, $0.001 par value CTSO The Nasdaq Stock Market LLC (Nasdaq Capital Market)


Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).


Emerging Growth Company ¨


If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ¨






Item 8.01 Other Events


On October 7, 2021, CytoSorbents Corporation (the “Company”) issued a press release announcing the public availability of preliminary data abstracts from two separate endocarditis studies, including the REMOVE study, to be presented at the upcoming European Association for Cardio-Thoracic Surgery (EACTS) annual meeting taking place in Barcelona, Spain from October 13-16, 2021, where more extensive data are expected to be made available. A copy of the press release is attached as Exhibit 99.1 and incorporated by reference herein.


Item 9.01 Exhibits


(d) Exhibits


Exhibit No. Description
99.1 Press Release of the Company, dated October 7, 2021

Cover Page Interactive Data File (embedded with the Inline XBRL document) 







Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.



  By: /s/ Dr. Phillip P. Chan
  Name: Dr. Phillip P. Chan
  Title: Chief Executive Officer






CytoSorbents (NASDAQ:CTSO)
Historical Stock Chart
From Dec 2021 to Jan 2022 Click Here for more CytoSorbents Charts.
CytoSorbents (NASDAQ:CTSO)
Historical Stock Chart
From Jan 2021 to Jan 2022 Click Here for more CytoSorbents Charts.